AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Abivax Stock Soars 501.5% on Positive Ulcerative Colitis Trial Results
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jul 23, 2025 8:54 am ET1min read
Aime SummaryOn July 23, 2025, Abivax's stock experienced a remarkable surge, rising by 501.5% in pre-market trading, reflecting a significant boost in investor confidence.
This surge was primarily driven by the positive Phase 3 trial results for Obefazimod, Abivax's lead drug candidate for ulcerative colitis. The drug achieved its primary goals, demonstrating efficacy with a 19.3% and 13.4% placebo-adjusted response rate.
Investors responded positively to the news, as the successful trial results indicated a promising future for Abivax's treatment for ulcerative colitis. The company's stock price reflected this optimism, with a substantial increase in pre-market trading.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Sweetgreen (SG) Surged 5.41% in Pre-Market Trading on Strategic Expansion into Sacramento
Dec.26 2025
United States Antimony Surges 5.31% on Landmark DLA and Commercial Supply Contracts
Dec.26 2025
United States Antimony surges 5.31% on sharp reversal in investor sentiment ahead of session open.
Dec.26 2025
Autozi Internet surges 13.54% in pre-market trading as AI expansion and EV partnerships boost investor confidence.
Dec.26 2025
Strive Asset Management ASST surged 7.03% driven by 12.25% dividend hike and Bitcoin treasury strategy
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet